GSK plc (LON:GSK)
London
· Delayed Price · Currency is GBP · Price in GBX 1,407.50
-27.50 (-1.92%)
Aug 14, 2025, 3:11 PM BST
GSK plc Revenue
GSK plc had revenue of 7.99B GBP in the quarter ending June 30, 2025, with 1.29% growth. This brings the company's revenue in the last twelve months to 31.63B, up 0.59% year-over-year. In the year 2024, GSK plc had annual revenue of 31.38B with 3.46% growth.
Revenue (ttm)
31.63B
Revenue Growth
+0.59%
P/S Ratio
1.83
Revenue / Employee
460.90K
Employees
68,629
Market Cap
57.85B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 31.38B | 1.05B | 3.46% |
| Dec 31, 2023 | 30.33B | 1.00B | 3.42% |
| Dec 31, 2022 | 29.32B | 4.63B | 18.74% |
| Dec 31, 2021 | 24.70B | 342.00M | 1.40% |
| Dec 31, 2020 | 24.35B | -9.40B | -27.85% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 41.24B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| ConvaTec Group | 1.72B |
| Hikma Pharmaceuticals | 2.35B |
| Oxford Nanopore Technologies | 183.19M |
| HUTCHMED (China) | 439.54M |
| Genus | 671.60M |
GSK plc News
- 23 hours ago - Mersana targets reporting initial Emi-Le expansion data in H2 2025 while achieving $15M GSK milestone - Seeking Alpha
- 23 hours ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK - GlobeNewsWire
- 3 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK - PRNewsWire
- 3 days ago - GSK bid to expand Blujepa label for gonorrhea granted FDA priority review - Seeking Alpha
- 3 days ago - GSK's antibiotic drug gepotidacin gets priority review by FDA - Reuters
- 4 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK - GlobeNewsWire
- 5 days ago - Drugmaker GSK lands £372m in Covid jab pact - This is Money
- 6 days ago - GSK, CureVac to receive $740M as COVID vaccine patent dispute with Pfizer, BioNTech settled - Seeking Alpha